Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340988 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
A Phase 1 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02340988 is a Phase 1 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 36 participants.
The verdict
NCT02340988, a Phase 1 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the drug interaction potential and time course of the effect of oritavancin on warfarin pharmacokinetics in an open label, single arm manner.
Interventions
- DRUG Single-Dose IV Oritavancin Diphosphate and Warfarin
- DRUG Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02340988
The ClinicalTrials.gov registry entry for NCT02340988 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Single-Dose IV Oritavancin Diphosphate and Warfarin is the first listed.
NCT02340988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02340988 about?
NCT02340988 is a clinical study titled "Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects". The purpose of this study is to assess the drug interaction potential and time course of the effect of oritavancin on warfarin pharmacokinetics in an open label, single arm manner.
What is the current status of trial NCT02340988?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2015-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02340988?
The interventions under investigation include: Single-Dose IV Oritavancin Diphosphate and Warfarin (DRUG), Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose (DRUG).
Who is sponsoring clinical trial NCT02340988?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.